FLT3 and acute myeloid leukemia: The CALGB conducted a randomized, placebo‐controlled Phase III trial (RATIFY) in treatment‐naive FLT3‐mutated AML patients <60 years encompassing induction chemotherapy and four consolidation cycles of high‐dose cytarabine combined with placebo or midostaurin, followed by midostaurin maintenance or placebo for 1 year 32.